Health
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients – News-Medical.Net
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress s to expand the Phase II clinical trial at…
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude…
-
General11 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News17 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General23 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
General12 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery